哮喘的个体化医学：行动的时刻：“呼吸疾病个体化医学”系列第 1 卷，主编 Renaud Louis 和 Nicolas Roche。
Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.
机构信息
National Heart and Lung Institute, Imperial College London, London, UK
Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, London, UK.
出版信息
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0064-2017. Print 2017 Sep 30.
Abstract
Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can be obtained. Biomarkers can help differentiate between these phenotypes and pinpoint patients suitable for specific targeted therapies - the basis for personalised medicine. Biomarkers need to be linked to point-of-care biomarkers that may be measured readily in exhaled breath, blood or urine. The potential for using mobile healthcare approaches will help patient enpowerment, an essential tool for personalised medicine. Personalised medicine in asthma is not far off - it is already here, but we need more tools and implements to carry it out for the benefit of our patients.
摘要
哮喘是一种异质性疾病，由不同途径驱动的几种表型组成。为了定义这些表型或内型（由机制定义的表型），对各种组学平台进行无偏聚类的方法将产生分子表型，从中可以获得复合生物标志物。生物标志物可帮助区分这些表型，并确定适合特定靶向治疗的患者 - 这是个性化医学的基础。生物标志物需要与可在呼气、血液或尿液中轻松测量的即时护理生物标志物相关联。使用移动医疗保健方法的潜力将有助于增强患者的权能，这是个性化医学的重要工具。哮喘的个性化医学已经不远了 - 它已经存在，但我们需要更多的工具和手段来实施它，以造福我们的患者。
相似文献
1
Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.哮喘的个体化医学：行动的时刻：“呼吸疾病个体化医学”系列第 1 卷，主编 Renaud Louis 和 Nicolas Roche。
Eur Respir Rev. 2017 Sep 27;26(145). doi: 10.1183/16000617.0064-2017. Print 2017 Sep 30.
2
Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.特发性肺纤维化：呼吸疾病个体化医学专辑 6 卷 本 主译：Louis Renaud, Roche Nicolas
Eur Respir Rev. 2018 Apr 13;27(148). doi: 10.1183/16000617.0117-2017. Print 2018 Jun 30.
3
Precision medicine in asthma: linking phenotypes to targeted treatments.哮喘精准医学：表型与靶向治疗相关联。
Curr Opin Pulm Med. 2018 Jan;24(1):4-10. doi: 10.1097/MCP.0000000000000434.
4
Personalised medicine in asthma: from curative to preventive medicine.哮喘的个性化医疗：从治愈性医学到预防性医学。
Eur Respir Rev. 2017 Jan 3;26(143). doi: 10.1183/16000617.0010-2016. Print 2017 Jan.
5
Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.气道疾病个性化治疗内型分析（ADEPT）纵向分析研究中的哮喘特征与生物标志物
Respir Res. 2015 Nov 17;16:142. doi: 10.1186/s12931-015-0299-y.
6
Asthma Phenotypes and Endotypes: Implications for Personalised Therapy.哮喘表型和内型：对个体化治疗的启示。
BioDrugs. 2017 Oct;31(5):393-408. doi: 10.1007/s40259-017-0242-5.
7
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.生物制品个体化医学治疗严重 2 型哮喘：现状与展望。
MAbs. 2018 Jan;10(1):34-45. doi: 10.1080/19420862.2017.1392425. Epub 2017 Nov 14.
8
Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma?我们是否满足了哮喘的表型和精准医学的承诺？
Physiol Rev. 2020 Jul 1;100(3):983-1017. doi: 10.1152/physrev.00023.2019. Epub 2020 Jan 9.
9
Future treatment for asthma.哮喘的未来治疗方法。
Eur Respir Rev. 2016 Mar;25(139):77-92. doi: 10.1183/16000617.0069-2015.
10
Control of asthma in real life: still a valuable goal?现实生活中哮喘的控制：仍是一个有价值的目标吗？
Eur Respir Rev. 2015 Jun;24(136):361-9. doi: 10.1183/16000617.00001615.
引用本文的文献
1
Unraveling the Molecular Complexity of Asthma: Insights from a Multicohort Transcriptome Study.解析哮喘的分子复杂性：来自多队列转录组研究的见解
Am J Respir Cell Mol Biol. 2025 Jul;73(1):6-8. doi: 10.1165/rcmb.2024-0497ED.
2
Automated Interpretation of Lung Sounds by Deep Learning in Children With Asthma: Scoping Review and Strengths, Weaknesses, Opportunities, and Threats Analysis.深度学习在儿童哮喘肺部声音自动分析中的应用：范围综述及优势、劣势、机会和威胁分析。
J Med Internet Res. 2024 Aug 23;26:e53662. doi: 10.2196/53662.
3
Overall perspective of electrospun semiconductor metal oxides as high-performance gas sensor materials for NO detection.电纺半导体金属氧化物作为用于检测NO的高性能气体传感器材料的总体概述。
RSC Adv. 2024 Mar 5;14(11):7806-7824. doi: 10.1039/d3ra08119b. eCollection 2024 Feb 29.
4
How have we measured trial outcomes of asthma attack treatment? A systematic review.我们如何衡量哮喘发作治疗的试验结果？一项系统评价。
ERJ Open Res. 2024 Feb 26;10(1). doi: 10.1183/23120541.00660-2023. eCollection 2024 Jan.
5
Metabolomics in Animal Models of Bronchial Asthma and Its Translational Importance for Clinics.支气管哮喘动物模型中的代谢组学及其对临床的转化重要性。
Int J Mol Sci. 2023 Dec 29;25(1):459. doi: 10.3390/ijms25010459.
6
Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.开放三联和闭合三联吸入疗法治疗未控制哮喘患者的疗效比较。
Adv Respir Med. 2023 Jul 4;91(4):288-300. doi: 10.3390/arm91040023.
7
[Biologics for the treatment of severe asthma: Current status report 2023].[2023年治疗重度哮喘的生物制剂：现状报告]
Tuberk Toraks. 2023 Jun;71(2):176-187. doi: 10.5578/tt.20239921.
8
[The profile of severe asthmatics: Results from a specialized asthma clinic].[重度哮喘患者概况：一家专业哮喘诊所的研究结果]
Tuberk Toraks. 2023 Jun;71(2):156-165. doi: 10.5578/tt.20239919.
9
A Predictive Machine Learning Tool for Asthma Exacerbations: Results from a 12-Week, Open-Label Study Using an Electronic Multi-Dose Dry Powder Inhaler with Integrated Sensors.一种用于哮喘急性加重的预测性机器学习工具：使用带有集成传感器的电子多剂量干粉吸入器进行的为期12周的开放标签研究结果。
J Asthma Allergy. 2022 Nov 11;15:1623-1637. doi: 10.2147/JAA.S377631. eCollection 2022.
10
Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma.白细胞重分布作为严重哮喘中皮质类固醇抵抗的免疫生物标志物。
Clin Exp Allergy. 2022 Oct;52(10):1183-1194. doi: 10.1111/cea.14128. Epub 2022 Apr 1.
本文引用的文献
1
Severe eosinophilic asthma: a roadmap to consensus.重度嗜酸性粒细胞性哮喘：共识路线图
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.00634-2017. Print 2017 May.
2
Perspectives of patients and healthcare professionals on mHealth for asthma self-management.患者和医疗保健专业人员对哮喘自我管理的移动医疗的看法。
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.01966-2016. Print 2017 May.
3
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.美泊利珠单抗附加疗法对严重嗜酸性粒细胞性哮喘（MUSCA）患者健康相关生活质量和哮喘控制标志物的疗效：一项随机、双盲、安慰剂对照、平行分组、多中心、3b 期临床试验。
Lancet Respir Med. 2017 May;5(5):390-400. doi: 10.1016/S2213-2600(17)30125-X. Epub 2017 Apr 5.
4
T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED.在 U-BIOPRED 中使用痰液转录组学研究哮喘的 T 辅助细胞 2（Th2）和非-Th2 分子表型。
Eur Respir J. 2017 Feb 8;49(2). doi: 10.1183/13993003.02135-2016. Print 2017 Feb.
5
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics.U-BIOPRED 临床成人哮喘聚类与痰液组学的一个子集相关。
J Allergy Clin Immunol. 2017 Jun;139(6):1797-1807. doi: 10.1016/j.jaci.2016.08.048. Epub 2016 Oct 20.
6
Clinical profile of patients with adult-onset eosinophilic asthma.成人发病的嗜酸性粒细胞性哮喘患者的临床特征
ERJ Open Res. 2016 May 26;2(2). doi: 10.1183/23120541.00100-2015. eCollection 2016 Apr.
7
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.贝那鲁肽治疗高剂量吸入性皮质激素和长效β-agonists 控制不佳的严重哮喘患者的疗效和安全性（SIROCCO）：一项随机、多中心、安慰剂对照的 3 期临床试验。
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
8
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.美泊利珠单抗治疗嗜酸粒细胞性哮喘的疗效分层：基于基线嗜酸粒细胞阈值的 DREAM 和 MENSA 研究的二次分析。
Lancet Respir Med. 2016 Jul;4(7):549-556. doi: 10.1016/S2213-2600(16)30031-5. Epub 2016 May 10.
9
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.血液嗜酸性粒细胞计数与未来年度哮喘疾病负担：一项英国队列研究。
Lancet Respir Med. 2015 Nov;3(11):849-58. doi: 10.1016/S2213-2600(15)00367-7. Epub 2015 Oct 19.
10
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.生物标志物鉴定：迈向生物标志物开发、监管认可及应用的多方利益相关者框架
Clin Pharmacol Ther. 2015 Jul;98(1):34-46. doi: 10.1002/cpt.136. Epub 2015 Jun 6.
Zotero 插件